Advertisement
09/29/2021

Upsher-Smith intros three new dosage strengths for generic Absorica

Upsher-Smith is partnering with Mayne Pharma to expand product access.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Upsher-Smith is introducing three additional strengths of isotretinoin capsules, a medication for acne.

The company now offers isotretinoin capsules in 10 mg, 20 mg, 30 mg and 40 mg strengths. Upsher-Smith’s product is the generic of Sun Pharma’s Absorica.

This development program is part of a multi-year, multi-product collaboration between Upsher-Smith and New Zealand-based, Douglas Pharmaceutical which is a leading producer of isotretinoin around the globe and will manufacture the product for Upsher-Smith.

[Read more: Rolling with the punches: Generics firms innovate, expand scope to stay competitive]

As part of its commercialization strategy, Upsher-Smith will distribute the four strengths of isotretinoin capsules under its own label and has also entered into a private label supply and distribution agreement with Mayne Pharma.

Based on the agreement, Mayne Pharma will serve as Upsher-Smith’s private label distribution partner in the United States for isotretinoin capsules manufactured under the Upsher-Smith abbreviated new drug application. The isotretinoin capsule market had U.S. sales of approximately $157 million for the 12 months ended July 2021, according to IQVIA.

[Read more: Upsher-Smith expands Access Pathways Program for commercially insured migraine patients]

“The launch of isotretinoin apsules marks an important milestone as we continue to grow and diversify our product portfolio,” said Rusty Field, president and CEO of Upsher-Smith. “This product is among others that we’ve developed through our collaboration with Douglas. In addition, our supply and distribution agreement with Mayne Pharma has the potential to significantly impact this market given the company’s established network of healthcare professionals and vast experience in this market.”

Jeff Douglas, managing director of Douglas added, “This is an exciting time for both Douglas and Upsher-Smith, two companies that are committed to delivering quality, high-value pharmaceutical products. The combination of our development and manufacturing expertise in a variety of therapeutic areas and Upsher-Smith’s experience in the U.S. commercializing generics and branded generics makes the launch of this product particularly meaningful. We look forward to our continued partnership.”

[Read more: Upsher-Smith offers help to people with migraines during Migraine month]

“Implementing strategic partnerships and bringing specialty brands and generic products to the U.S. market are fundamental to our company’s continued growth,” added Scott Richards, CEO, Mayne Pharma. “We are pleased to partner with Upsher-Smith and look forward to leveraging our established commercial capabilities to expand patient access to Isotretinoin Capsules.”

For questions about ordering, please call Upsher-Smith at 1-800-654-2299. 

    Advertisement
    Advertisement